Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven P Marso

Showing results (51-60 of 143) with videos related to

Pageof 15
Sort By:
Circulation|January 24, 2007
Quantifying improvement in symptoms, functioning, and quality of life after peripheral endovascular revascularizationDavid M Safley, John A House, Steven B Laster, et al.
American Heart Journal|March 5, 2013
Comparison of costs between transradial and transfemoral percutaneous coronary intervention: a cohort analysis from the Premier research databaseDavid M Safley, Amit P Amin, John A House, et al.
Journal of the American College of Cardiology|March 19, 2013
Pre-procedural estimate of individualized bleeding risk impacts physicians' utilization of bivalirudin during percutaneous coronary interventionSeshu C Rao, Adnan K Chhatriwalla, Kevin F Kennedy, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|May 2, 2018
DEVOTE 5: Evaluating the Short-Term Cost-Utility of Insulin Degludec Versus Insulin Glargine U100 in Basal-Bolus Regimens for Type 2 Diabetes in the UKRichard F Pollock, William J Valentine, Steven P Marso, et al.
The Lancet. Diabetes & Endocrinology|August 6, 2021
Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trialIan J Neeland, Steven P Marso, Colby R Ayers, et al.
The Lancet. Diabetes & Endocrinology|September 24, 2020
Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trialsJohannes F E Mann, Thomas Hansen, Thomas Idorn, et al.
Applied Health Economics and Health Policy|July 3, 2019
Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16)Richard F Pollock, William J Valentine, Steven P Marso, et al.
Journal of the American College of Cardiology|August 23, 2014
Blood transfusion during acute myocardial infarction: association with mortality and variability across hospitalsAdam C Salisbury, Kimberly J Reid, Steven P Marso, et al.
JACC. Cardiovascular Interventions|July 25, 2009
Drug-eluting stents and the use of percutaneous coronary intervention among patients with class I indications for coronary artery bypass surgery undergoing index revascularization: analysis from the NCDR (National Cardiovascular Data Registry)Andrew D Frutkin, Jason B Lindsey, Sameer K Mehta, et al.
The American Journal of Cardiology|December 26, 2007
Outcomes of 1,090 consecutive, elective, nonselected percutaneous coronary interventions at a community hospital without onsite cardiac surgeryAndrew D Frutkin, Sameer K Mehta, Taral Patel, et al.
Pageof 15

Showing results (51-60 of 143) with videos related to

Sort By:
Pageof 15
Circulation|January 24, 2007
Quantifying improvement in symptoms, functioning, and quality of life after peripheral endovascular revascularizationDavid M Safley, John A House, Steven B Laster, et al.
American Heart Journal|March 5, 2013
Comparison of costs between transradial and transfemoral percutaneous coronary intervention: a cohort analysis from the Premier research databaseDavid M Safley, Amit P Amin, John A House, et al.
Journal of the American College of Cardiology|March 19, 2013
Pre-procedural estimate of individualized bleeding risk impacts physicians' utilization of bivalirudin during percutaneous coronary interventionSeshu C Rao, Adnan K Chhatriwalla, Kevin F Kennedy, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|May 2, 2018
DEVOTE 5: Evaluating the Short-Term Cost-Utility of Insulin Degludec Versus Insulin Glargine U100 in Basal-Bolus Regimens for Type 2 Diabetes in the UKRichard F Pollock, William J Valentine, Steven P Marso, et al.
The Lancet. Diabetes & Endocrinology|August 6, 2021
Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trialIan J Neeland, Steven P Marso, Colby R Ayers, et al.
The Lancet. Diabetes & Endocrinology|September 24, 2020
Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trialsJohannes F E Mann, Thomas Hansen, Thomas Idorn, et al.
Applied Health Economics and Health Policy|July 3, 2019
Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16)Richard F Pollock, William J Valentine, Steven P Marso, et al.
Journal of the American College of Cardiology|August 23, 2014
Blood transfusion during acute myocardial infarction: association with mortality and variability across hospitalsAdam C Salisbury, Kimberly J Reid, Steven P Marso, et al.
JACC. Cardiovascular Interventions|July 25, 2009
Drug-eluting stents and the use of percutaneous coronary intervention among patients with class I indications for coronary artery bypass surgery undergoing index revascularization: analysis from the NCDR (National Cardiovascular Data Registry)Andrew D Frutkin, Jason B Lindsey, Sameer K Mehta, et al.
The American Journal of Cardiology|December 26, 2007
Outcomes of 1,090 consecutive, elective, nonselected percutaneous coronary interventions at a community hospital without onsite cardiac surgeryAndrew D Frutkin, Sameer K Mehta, Taral Patel, et al.
Pageof 15